Kamada

KMDA · Nasdaq · Israel

Share price · KMDA

$8.07+0.18 (+2.28%) 3M

close as of 2026-11-18 · 24h delayed · vol 159K (1.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when KMDA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+5.1%
  2. 5 Oct 2026-3.7%
  3. 13 Aug 2026+5.5%
  4. 13 May 2026-6.8%

    Nothing announced by KMDA that day or the session before.

  5. 17 Feb 2026+6.8%

    Nothing announced by KMDA that day or the session before.

  6. 26 Jan 2026+8.1%

    Nothing announced by KMDA that day or the session before.

  7. 20 Jan 2026-4.4%

    Nothing announced by KMDA that day or the session before.

  8. 15 Jan 2026+3.3%

    Nothing announced by KMDA that day or the session before.

Share of unusual movement by asset

For each asset, the share of KMDA's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—84%

No dated announcements about its assets since 14 Oct 2025.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
HBsAgProtein / enzyme therapeutic
Chronic Hepatitis B

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (12)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$47M$2.6M$72M—$10M operating cash flowreport ↗
View 11 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2$45M$3.2M$66M—$8.0M operating cash flowreport ↗
2025-Q1$44M$4.3M$76M—-$0.5M operating cash flowreport ↗
2024-Q3$42M$3.4M$72M—$22M operating cash flowreport ↗
2024-Q2$42M$4.8M$57M—$14M operating cash flowreport ↗
2024-Q1<$0.1M$0$0.1M—$0 operating cash flowreport ↗
2023-Q3<$0.1M$0$0.1M—$0 operating cash flowreport ↗
2023-Q2$37M$4.3M$22M—$1.8M operating cash flowreport ↗
2023-Q1$31M$3.2M$27M$1.8M-$2.9M operating cash flowreport ↗
2022-Q3$32M$3.1M$31M—$5.5M operating cash flowreport ↗
2022-Q2$24M$2.6M$30M$3.9M$11M operating cash flowreport ↗
2022-Q1$28M$4.4M$22M$1.8M$5.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$180M$13M$75M—$25M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$161M$15M$78M—$48M operating cash flowreport ↗
2023-FY$143M$14M$56M—$4.3M operating cash flowreport ↗
2022-FY$129M$13M$34M$0.6M$29M operating cash flowreport ↗
2021-FY$104M$11M$19M$0.6M-$8.8M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($1.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-14Tsur David · directorOpen-market sale22,827$8.18$187KForm 4
2026-09-14Livneh Nir · VP, General CounselOption exercise10,000$5.37$54KForm 4
2026-09-14Brenner Yael · VP QualityOption exercise5,000$5.93$30KForm 4
2026-09-14Livneh Nir · VP, General CounselTax withholding3,459$8.35$29KForm 4
2026-09-14Brenner Yael · VP QualityTax withholding1,371$8.36$11KForm 4
2026-09-14Livneh Nir · VP, General CounselOption exercise (derivative)10,000——Form 4
2026-09-14Brenner Yael · VP QualityOption exercise5,000$5.93$30KForm 4
2026-09-14Brenner Yael · VP QualityTax withholding1,371$8.36$11KForm 4